Effectiveness and safety of the full-dose combination therapy with perindopril A and indapamide (10 mg/2,5 mg) in patients with arterial hypertension

Abstract

Aim. To assess the effectiveness and safety of the full-dose combination therapy with perindopril (10 mg) and indapamide (2,5 mg) in patients with arterial hypertension (AH). Material and methods. The simple, non-randomised, prospective study included 36 patients with Stage 1-2 AH. Treatment effectiveness was assessed by the reduction in office blood pressure (BP) levels, results of the 24-hour BP monitoring (BPM), morning BP surge (MS), BP load area and time, BP variability, and diurnal index. Safety parameters included the levels of sodium, potassium, glucose, hepatic aminotransferases, urea, creatinine, and the presence of hypotension episodes. Statistical analysis was performed in SPSS 12. Results. The three-month therapy resulted in the achievement of target levels of systolic and diastolic BP (SBP, DBP) in 83% and 100% of the patients, respectively. According to the 24-hour BPM results, there was a significant reduction in the levels of SBP24 (from 148,3±18,2 to 134±11,1 mm Hg; p=0,001), DBP (from 84,8±12,3 to 76,9±9,1 mm Hg; p=0,001), and pulse BP (from 64,0±14,6 to 58,4±9,6 mm Hg; p=0,012). There was also a significant reduction in the load time indices of SBPday (from 72,5% (95% confidence interval, CI, 43,3-95,3) to 46,5% (95% CI 16,3-64,0); p=0,001) and DBPday (from 84,5% (54,0-100,0) to 57,0% (35,0-82,3); p=0,002). MS velocity decreased for both SBP (from 16,4 (12,5-25,1) to 12,7 (10,8-15,8) mm Hg (p=0,017) and DBP (from 15,8 (10,2-22,0) to 12,2 (9,3-17,8) mm Hg (p=0,019). During the therapy course, no hypotension episodes or marked changes in blood biochemistry and electrolyte parameters were registered. Conclusion. Initiating antihypertensive therapy with a full-dose combination of perindopril and indapamide was both effective and safe.